BECTON DICKINSON & CO
BDXAPI behind this page
BDX Q2 2026 request
Playground key active
/api/financials?ticker=BDX&year=2026&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2026 | Q2 2025 | YoY |
|---|---|---|---|
| Revenue | 4,714 | 4,480 | +5.2% |
Show Business Segments breakouts |
|||
| BioPharma Systems · BioPharma Systems | 590 | 575 | +2.6% |
| BioPharma Systems · Non Us | 411 | 426 | -3.5% |
| BioPharma Systems · Operating Segments | 590 | 575 | +2.6% |
| BioPharma Systems · US | 178 | 149 | +19.5% |
| Connected Care · Advanced Patient Monitoring | 292 | 257 | +13.6% |
| Connected Care · Medication Management Solutions | 829 | 811 | +2.2% |
| Connected Care · Non Us | 112 | 102 | +9.8% |
| Connected Care · Non Us | 168 | 149 | +12.8% |
| Connected Care · Non Us | 280 | 251 | +11.6% |
| Connected Care · Operating Segments | 1,120 | 1,068 | +4.9% |
| Connected Care · US | 180 | 155 | +16.1% |
| Connected Care · US | 660 | 662 | -0.3% |
| Connected Care · US | 840 | 817 | +2.8% |
| Interventional · Non Us | 236 | 212 | +11.3% |
| Interventional · Non Us | 109 | 94 | +16.0% |
| Interventional · Non Us | 79 | 77 | +2.6% |
| Interventional · Non Us | 423 | 384 | +10.2% |
| Interventional · Operating Segments | 1,357 | 1,264 | +7.4% |
| Interventional · Peripheral Intervention | 515 | 481 | +7.1% |
| Interventional · Surgery | 411 | 383 | +7.3% |
| Interventional · Urology and Critical Care | 430 | 400 | +7.5% |
| Interventional · US | 279 | 269 | +3.7% |
| Interventional · US | 303 | 289 | +4.8% |
| Interventional · US | 351 | 323 | +8.7% |
| Interventional · US | 933 | 880 | +6.0% |
| Medical Essentials · Medication Delivery Solutions | 1,163 | 1,117 | +4.1% |
| Medical Essentials · Non Us | 451 | 430 | +4.9% |
| Medical Essentials · Non Us | 231 | 213 | +8.5% |
| Medical Essentials · Non Us | 682 | 643 | +6.1% |
| Medical Essentials · Operating Segments | 1,647 | 1,573 | +4.7% |
| Medical Essentials · Specimen Management | 484 | 456 | +6.1% |
| Medical Essentials · US | 712 | 687 | +3.6% |
| Medical Essentials · US | 253 | 242 | +4.5% |
| Medical Essentials · US | 965 | 929 | +3.9% |
Show Geography breakouts |
|||
| Non Us | 1,797 | 1,704 | +5.5% |
| US | 2,917 | 2,776 | +5.1% |
| Cost of Revenue | 2,560 | 2,619 | -2.3% |
Show Business Segments breakouts |
|||
| BioPharma Systems · Operating Segments | 316 | 306 | +3.3% |
| Connected Care · Operating Segments | 490 | 478 | +2.5% |
| Interventional · Operating Segments | 429 | 401 | +7.0% |
| Medical Essentials · Operating Segments | 835 | 743 | +12.4% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 2,070 | 1,928 | +7.4% |
| Total Costs & Expenses | 4,620 | 4,097 | +12.8% |
| Research & Development | 249 | 232 | +7.3% |
Show Business Segments breakouts |
|||
| BioPharma Systems · Operating Segments | 17 | 18 | -5.6% |
| Connected Care · Operating Segments | 90 | 74 | +21.6% |
| Interventional · Operating Segments | 72 | 63 | +14.3% |
| Medical Essentials · Operating Segments | 53 | 48 | +10.4% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 232 | 203 | +14.3% |
| Selling, General & Administrative | 1,213 | 1,117 | +8.6% |
Show Business Segments breakouts |
|||
| BioPharma Systems · Operating Segments | 32 | 28 | +14.3% |
| Connected Care · Operating Segments | 190 | 161 | +18.0% |
| Interventional · Operating Segments | 277 | 236 | +17.4% |
| Medical Essentials · Operating Segments | 185 | 164 | +12.8% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 684 | 589 | +16.1% |
| Operating Expenses (Q) | — | — | — |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -595 | -636 | +6.4% |
| Operating Income | 93 | 383 | -75.7% |
Show Business Segments breakouts |
|||
| BioPharma Systems · Operating Segments | 225 | 224 | +0.4% |
| Connected Care · Operating Segments | 347 | 353 | -1.7% |
| Interventional · Operating Segments | 579 | 565 | +2.5% |
| Medical Essentials · Operating Segments | 574 | 617 | -7.0% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 1,724 | 1,759 | -2.0% |
| Interest Expense | -149 | -150 | +0.7% |
| Interest Income | 9 | 5 | +80.0% |
| Other Non-Operating Income (Expense) | 86 | -36 | +338.9% |
| Income Before Taxes | 39 | 201 | -80.6% |
| Income Tax Expense (Benefit) | 76 | 43 | +76.7% |
| Comprehensive Income | -217 | 268 | -181.0% |
| EPS (Basic) | -1.11 | 1.07 | -203.7% |
| EPS (Diluted) | -1.11 | 1.07 | -203.7% |
| Wtd Avg Shares (Basic) | 280,640 | 287,293 | -2.3% |
| Wtd Avg Shares (Diluted) | 280,640 | 287,737 | -2.5% |
| Interest Income Expense Net (Q) | — | — | — |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 140 | — | — |
Balance Sheet
| Metric | Q2 2026 | Q2 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 813 | 667 | +21.9% |
| Restricted Cash And Investments Current | 202 | 80 | +152.5% |
| Other Short Term Investments | 3 | 16 | -81.2% |
| Accounts Receivable | 2,205 | 3,029 | -27.2% |
| Inventory Raw Materials Net Of Reserves | 801 | 892 | -10.2% |
| Inventory Work In Process Net Of Reserves | 396 | 487 | -18.7% |
| Inventory Finished Goods Net Of Reserves | 2,161 | 2,344 | -7.8% |
| Inventory | 3,357 | 3,723 | -9.8% |
| Other Assets Current | 1,432 | 1,150 | +24.5% |
| Total Current Assets | 8,012 | 8,666 | -7.5% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 6,082 | 6,646 | -8.5% |
| Goodwill | 25,955 | — | — |
Show Business Segments breakouts |
|||
| BioPharma Systems | 96 | — | — |
| Connected Care | 6,095 | — | — |
| Interventional | 12,755 | — | — |
| Medical Essentials | 7,010 | — | — |
| Other Non-Current Assets | 2,434 | 2,577 | -5.5% |
| Total Assets | 50,832 | 54,467 | -6.7% |
| Intangible Assets | 8,348 | 10,118 | -17.5% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Relationships | 2,005 | 2,434 | -17.6% |
| Developed Technology Rights | 5,894 | 7,171 | -17.8% |
| Intellectual Property | 450 | 513 | -12.3% |
| Other Assets | |||
| Property Plant And Equipment Gross | 13,552 | 14,409 | -5.9% |
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | 7,470 | 7,763 | -3.8% |
| Core And Developed Technology Net | 5,894 | 7,171 | -17.8% |
| Finite Lived Customer Relationships Net | 2,005 | 2,434 | -17.6% |
| Other Intangible Assets Net | 450 | 530 | -15.1% |
| Current Liabilities | |||
| Debt Current | 2,573 | 1,604 | +60.4% |
| Accounts Payable And Accrued Liabilities Current | 5,934 | 6,087 | -2.5% |
| Total Current Liabilities | 8,507 | 7,691 | +10.6% |
| Non-Current Liabilities | |||
| Long-Term Debt | 14,706 | — | — |
Show Debt Instrument breakouts |
|||
| Debentures due 2027 · Long Term Debt | 33 | — | — |
| Debentures due 2028 · Long Term Debt | 28 | — | — |
| Notes 3.794% due 2050 · Long Term Debt | 260 | — | — |
| Notes 4.669% due 2047 · Long Term Debt | 650 | — | — |
| Notes 4.685% due 2044 · Long Term Debt | 480 | — | — |
| Notes 4.875% due 2044 · Long Term Debt | 99 | — | — |
| Notes 5.000% due 2040 · Long Term Debt | 37 | — | — |
| Notes 5.081% due 2029 · Long Term Debt | 443 | — | — |
| Notes 6.000% due 2039 · Long Term Debt | 61 | — | — |
| Notes 6.700% notes due 2026 · Short Term Debt | 37 | — | — |
| Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent | 1,026 | 871 | +17.8% |
| Other Non-Current Liabilities | 2,460 | 2,998 | -17.9% |
| Stockholders' Equity | |||
| Common Stock | 371 | 371 | 0.0% |
| Additional Paid In Capital Common Stock | 19,768 | — | — |
Show Share Repurchase Program breakouts |
|||
| Accelerated Share Repurchase Program | 400 | 150 | +166.7% |
| Retained Earnings | 17,391 | 16,150 | +7.7% |
| Common Stock Shares Held In Employee Trust1 | 26 | 26 | 0.0% |
| Treasury Stock Value | -11,660 | -9,561 | -22.0% |
| Accumulated Other Comprehensive Income | -1,764 | -1,716 | -2.8% |
| Total Stockholders' Equity | 24,133 | 25,241 | -4.4% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -626 | -541 | -15.7% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | 105 | 72 | +45.8% |
| Accumulated Net Unrealized Investment Gain Loss | -3 | -1 | -200.0% |
| Accumulated Other Comprehensive Income | -1,764 | -1,716 | -2.8% |
| Accumulated Translation Adjustment | -1,239 | -1,246 | +0.6% |
| Additional Paid In Capital | 19,768 | 19,971 | -1.0% |
| Common Stock | 371 | 371 | 0.0% |
| Deferred Compensation Share Based Payments | 26 | 26 | 0.0% |
| Retained Earnings | 17,391 | 16,150 | +7.7% |
| Treasury Stock Common | -11,660 | -9,561 | -22.0% |
| Total Liabilities & Equity | 50,832 | 54,467 | -6.7% |
Cash Flow Statement
| Metric | YTD Q2 2026 | YTD Q2 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Net Income (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Retained Earnings | -311 | 308 | -201.0% |
| Net Income | 72 | 611 | -88.2% |
| Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity | -202 | 306 | -166.0% |
Show Disposal Group Classification breakouts |
|||
| Discontinued Operations Disposed Of By Means Other Than Sale Spinoff | -202 | 306 | -166.0% |
| Income Loss From Continuing Operations | 274 | 304 | -9.9% |
| Depreciation & Amortization | 1,134 | 1,131 | +0.3% |
Show Business Segments breakouts |
|||
| BioPharma Systems · Operating Segments | 62 | 62 | 0.0% |
| Connected Care · Operating Segments | 388 | 394 | -1.5% |
| Interventional · Operating Segments | 389 | 399 | -2.5% |
| Medical Essentials · Operating Segments | 288 | 270 | +6.7% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 6 | 6 | 0.0% |
| Stock-Based Compensation | 149 | 131 | +13.7% |
| Deferred Income Taxes And Tax Credits | -44 | -259 | +83.0% |
| Increase Decrease In Operating Capital | -417 | -1,070 | +61.0% |
| Increase Decreasein Pension Benefit Obligation | -4 | -3 | -33.3% |
| Asset Impairment Charges | 450 | — | — |
| Asset Impairment Charges (Q) | — | — | — |
Show Location, Statement of Financial Position, Activity, Accrual [Axis] breakouts |
|||
| Core and Developed Technology, Net | 134 | — | — |
| Property Plant And Equipment | 238 | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Developed Technology Rights | 134 | — | — |
| Gains Losses On Extinguishment Of Debt | -122 | — | — |
Show Debt Instrument breakouts |
|||
| Debentures due 2027 | 1 | — | — |
| Debentures due 2028 | 1 | — | — |
| Notes 3.794% due 2050 | -52 | — | — |
| Notes 4.669% due 2047 | -49 | — | — |
| Notes 4.685% due 2044 | -38 | — | — |
| Notes 4.875% due 2044 | -13 | — | — |
| Notes 5.081% due 2029 | 20 | — | — |
| Notes 6.000% due 2039 | 7 | — | — |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | -122 | — | — |
| Other Operating Activities Cash Flow Statement | -91 | 254 | -135.8% |
| Net Cash Provided By Used In Operating Activities Continuing Operations | 1,328 | 489 | +171.6% |
| Investing Activities | |||
| Capital Expenditures | -233 | -219 | -6.4% |
| Payments For Proceeds From Investments | 23 | 413 | -94.4% |
| Other Investing Activities | -111 | -136 | +18.4% |
| Net Cash Provided By Used In Investing Activities Continuing Operations | -322 | 71 | -553.5% |
| Financing Activities | |||
| Proceeds From Repayments Of Short Term Debt | 328 | 340 | -3.5% |
| Proceeds From Spinoff Transaction | 3,857 | — | — |
| Proceeds From Spinoff Transaction (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Retained Earnings | 3.86 | — | — |
| Repayments Of Long Term Debt | -2,000 | -875 | -128.6% |
| Share Repurchases | -2,250 | -750 | -200.0% |
| Payments Of Dividends | -589 | -600 | +1.8% |
| Proceeds From Payments For Other Financing Activities | -63 | -81 | +22.2% |
| Net Cash Provided By Used In Financing Activities Continuing Operations | -716 | -1,966 | +63.6% |
| Other Cash Flow | |||
| Cash Provided By Used In Operating Activities Discontinued Operations | -73 | 368 | -119.8% |
| Cash Provided By Used In Investing Activities Discontinued Operations | -53 | -59 | +10.2% |
| Cash Provided By Used In Financing Activities Discontinued Operations | 71 | -3 | +2466.7% |
| Net Cash Provided By Used In Discontinued Operations | -55 | 306 | -118.0% |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 3 | -11 | +127.3% |
| Net Change in Cash | 238 | -1,111 | +121.4% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,015 | 681 | +49.0% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.